Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study)
Elisabeth Van Aken,1,2 Mérédis Favreau,3 Eva Ramboer,3 Kris Denhaerynck,4,5 Karen MacDonald,4 Ivo Abraham,4,6– 8 Heidi Brié3 1Department of Ophthalmology, AZ Sint-Elisabeth, Zottegem, Belgium; 2Department of Head and Skin, Ghent University, Ghent, Belgium;...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/512f9290bfa247a393a00710e745aaf8 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:512f9290bfa247a393a00710e745aaf8 |
|---|---|
| record_format |
dspace |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
diabetic macular edema ranibizumab best-corrected visual acuity central retinal thickness long-term effectiveness Ophthalmology RE1-994 |
| spellingShingle |
diabetic macular edema ranibizumab best-corrected visual acuity central retinal thickness long-term effectiveness Ophthalmology RE1-994 Van Aken E Favreau M Ramboer E Denhaerynck K MacDonald K Abraham I Brié H Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study) |
| description |
Elisabeth Van Aken,1,2 Mérédis Favreau,3 Eva Ramboer,3 Kris Denhaerynck,4,5 Karen MacDonald,4 Ivo Abraham,4,6– 8 Heidi Brié3 1Department of Ophthalmology, AZ Sint-Elisabeth, Zottegem, Belgium; 2Department of Head and Skin, Ghent University, Ghent, Belgium; 3Medical Department, Novartis Pharma, Vilvoorde, Belgium; 4Department of Research and Consulting, Matrix45, Tucson, AZ, USA; 5Department of Public Health, University of Basel, Basel, Switzerland; 6Center for Health Outcomes and Pharmacoeconomic Research, University of Arizona, Tucson, AZ, USA; 7Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA; 8Department of Family and Community Medicine, College of Medicine – Tucson, University of Arizona, Tucson, AZ, USACorrespondence: Heidi BriéN.V. Novartis Pharma S.A, Medialaan 40, B-1800 Vilvoorde, BelgiumTel +32.2.246.1774Email heidi.brie@novartis.comAim: Evaluate long-term real-world treatment patterns and associated effectiveness and safety outcomes in patients with diabetic macular edema (DME) treated ≥ 36 months with 0.5mg ranibizumab.Methods: Open-label observational effectiveness study in 9 Belgian clinics. Included were primary treated eyes of 55 DME patients between August 2014 and March 2015 and followed for 3.5± 1.8 years. Eyes were 21.8% treatment (TX)-naïve, 9.1% non-naïve with exclusive prior anti-VEGF treatment (PRIOR-anti-VEGF), and 63.6% non-naïve with other prior treatments (PRIOR-other). Intravitreal injections with ranibizumab were administered per ophthalmologists’ best clinical judgment. Trend testing of changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) over time occurred using mixed regression analysis.Results: The mean±SD number of treatments in the first year was 5.1± 3.0 (TX-naïve), 4.5± 2.7 (PRIOR-anti-VEGF) and 5.6± 3.1 (PRIOR-other). At 12 months, BCVA increased by 8.9± 16.4 letters from 59.7± 9.3 at baseline in TX-naïve (p< 0.0001), by 11.8± 9.9 from 61.6± 8.5 in PRIOR-anti-VEGF (p=0.03), and by 4.2± 10.6 from 58.2± 14.6 in PRIOR-other groups (p=0.0002). BCVA remained stable for the remainder of follow-up in all groups. CRT decreased over the first 2 months by monthly rates of − 43.8μm in TX-naïve (p=0.04), − 75.7μm in PRIOR-anti-VEGF (p=0.02), and − 65.8μm in PRIOR-other eyes (p=0.0003), showing stability afterwards. No unknown adverse events were recorded; a painful eye following injection was registered with a possible relationship to the treatment.Conclusion: This real-world study confirms the effectiveness of ranibizumab in preventing a decline in BCVA and demonstrated initial improvement and subsequent retention of BCVA in DME patients ≥ 36 months. Ranibizumab initially reduced and then maintained CRT. However, these data reveal that treatment intensity and BCVA and CRT outcomes are lower than those found in early efficacy trials. Under-treatment likely accounts for this efficacy-effectiveness gap. Yet, intravitreal ranibizumab is an effective and safe long-term treatment for DME under conditions of significant heterogeneity in patients and treatment patterns.Keywords: diabetic macular edema, ranibizumab, best-corrected visual acuity, central retinal thickness, long-term effectiveness |
| format |
article |
| author |
Van Aken E Favreau M Ramboer E Denhaerynck K MacDonald K Abraham I Brié H |
| author_facet |
Van Aken E Favreau M Ramboer E Denhaerynck K MacDonald K Abraham I Brié H |
| author_sort |
Van Aken E |
| title |
Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study) |
| title_short |
Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study) |
| title_full |
Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study) |
| title_fullStr |
Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study) |
| title_full_unstemmed |
Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study) |
| title_sort |
real-world outcomes in patients with diabetic macular edema treated long term with ranibizumab (vision study) |
| publisher |
Dove Medical Press |
| publishDate |
2020 |
| url |
https://doaj.org/article/512f9290bfa247a393a00710e745aaf8 |
| work_keys_str_mv |
AT vanakene realworldoutcomesinpatientswithdiabeticmacularedematreatedlongtermwithranibizumabvisionstudy AT favreaum realworldoutcomesinpatientswithdiabeticmacularedematreatedlongtermwithranibizumabvisionstudy AT ramboere realworldoutcomesinpatientswithdiabeticmacularedematreatedlongtermwithranibizumabvisionstudy AT denhaerynckk realworldoutcomesinpatientswithdiabeticmacularedematreatedlongtermwithranibizumabvisionstudy AT macdonaldk realworldoutcomesinpatientswithdiabeticmacularedematreatedlongtermwithranibizumabvisionstudy AT abrahami realworldoutcomesinpatientswithdiabeticmacularedematreatedlongtermwithranibizumabvisionstudy AT brieh realworldoutcomesinpatientswithdiabeticmacularedematreatedlongtermwithranibizumabvisionstudy |
| _version_ |
1718394452068794368 |
| spelling |
oai:doaj.org-article:512f9290bfa247a393a00710e745aaf82021-12-02T12:27:45ZReal-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study)1177-5483https://doaj.org/article/512f9290bfa247a393a00710e745aaf82020-12-01T00:00:00Zhttps://www.dovepress.com/real-world-outcomes-in-patients-with-diabetic-macular-edema-treated-lo-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Elisabeth Van Aken,1,2 Mérédis Favreau,3 Eva Ramboer,3 Kris Denhaerynck,4,5 Karen MacDonald,4 Ivo Abraham,4,6– 8 Heidi Brié3 1Department of Ophthalmology, AZ Sint-Elisabeth, Zottegem, Belgium; 2Department of Head and Skin, Ghent University, Ghent, Belgium; 3Medical Department, Novartis Pharma, Vilvoorde, Belgium; 4Department of Research and Consulting, Matrix45, Tucson, AZ, USA; 5Department of Public Health, University of Basel, Basel, Switzerland; 6Center for Health Outcomes and Pharmacoeconomic Research, University of Arizona, Tucson, AZ, USA; 7Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA; 8Department of Family and Community Medicine, College of Medicine – Tucson, University of Arizona, Tucson, AZ, USACorrespondence: Heidi BriéN.V. Novartis Pharma S.A, Medialaan 40, B-1800 Vilvoorde, BelgiumTel +32.2.246.1774Email heidi.brie@novartis.comAim: Evaluate long-term real-world treatment patterns and associated effectiveness and safety outcomes in patients with diabetic macular edema (DME) treated ≥ 36 months with 0.5mg ranibizumab.Methods: Open-label observational effectiveness study in 9 Belgian clinics. Included were primary treated eyes of 55 DME patients between August 2014 and March 2015 and followed for 3.5± 1.8 years. Eyes were 21.8% treatment (TX)-naïve, 9.1% non-naïve with exclusive prior anti-VEGF treatment (PRIOR-anti-VEGF), and 63.6% non-naïve with other prior treatments (PRIOR-other). Intravitreal injections with ranibizumab were administered per ophthalmologists’ best clinical judgment. Trend testing of changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) over time occurred using mixed regression analysis.Results: The mean±SD number of treatments in the first year was 5.1± 3.0 (TX-naïve), 4.5± 2.7 (PRIOR-anti-VEGF) and 5.6± 3.1 (PRIOR-other). At 12 months, BCVA increased by 8.9± 16.4 letters from 59.7± 9.3 at baseline in TX-naïve (p< 0.0001), by 11.8± 9.9 from 61.6± 8.5 in PRIOR-anti-VEGF (p=0.03), and by 4.2± 10.6 from 58.2± 14.6 in PRIOR-other groups (p=0.0002). BCVA remained stable for the remainder of follow-up in all groups. CRT decreased over the first 2 months by monthly rates of − 43.8μm in TX-naïve (p=0.04), − 75.7μm in PRIOR-anti-VEGF (p=0.02), and − 65.8μm in PRIOR-other eyes (p=0.0003), showing stability afterwards. No unknown adverse events were recorded; a painful eye following injection was registered with a possible relationship to the treatment.Conclusion: This real-world study confirms the effectiveness of ranibizumab in preventing a decline in BCVA and demonstrated initial improvement and subsequent retention of BCVA in DME patients ≥ 36 months. Ranibizumab initially reduced and then maintained CRT. However, these data reveal that treatment intensity and BCVA and CRT outcomes are lower than those found in early efficacy trials. Under-treatment likely accounts for this efficacy-effectiveness gap. Yet, intravitreal ranibizumab is an effective and safe long-term treatment for DME under conditions of significant heterogeneity in patients and treatment patterns.Keywords: diabetic macular edema, ranibizumab, best-corrected visual acuity, central retinal thickness, long-term effectivenessVan Aken EFavreau MRamboer EDenhaerynck KMacDonald KAbraham IBrié HDove Medical Pressarticlediabetic macular edemaranibizumabbest-corrected visual acuitycentral retinal thicknesslong-term effectivenessOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 14, Pp 4173-4185 (2020) |